Erythromelalgia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Erythromelalgia Market Outlook

Thelansis’s “Erythromelalgia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erythromelalgia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Erythromelalgia Overview

Erythromelalgia, a rare clinical syndrome, manifests with a triad of symptoms: redness, warmth, and burning pain, primarily affecting the extremities. Predominantly, it targets the lower extremities, notably the feet, while in some instances, it can involve the upper extremities, specifically the hands. Drenth and Michiels differentiated between erythromelalgia and erythermalgia based on their responsiveness to aspirin, resulting in three established categories:

1. Erythromelalgia in thrombocythemia, which is platelet-mediated and responds to aspirin. This occurs in conjunction with essential thrombocytosis and polycythemia vera.
2. Primary erythermalgia is an idiopathic or inherited disorder known as aspirin-resistant erythermalgia of unknown origin.
3. Secondary erythermalgia, aspirin-resistant, and linked to various medical conditions.

Erythromelalgia in thrombocythemia is associated with essential thrombocytosis and polycythemia vera. Primary erythromelalgia may be either idiopathic or inherited, with the inherited form being an autosomal dominant neuropathy resulting from a gain-of-function mutation in the SCN9A, SCN10A, and SCN11A genes. These genes encode the alpha subunits of the voltage-gated sodium channels NaV 1.7, NaV 1.8, and NaV 1.9, respectively. Secondary erythromelalgia is attributed to various underlying causes, including myeloproliferative disorders like essential thrombocytosis, polycythemia vera, and myelofibrosis, as well as infectious agents (HIV, influenza, syphilis, and poxviruses), autoimmune diseases (systemic lupus erythematosus and rheumatoid arthritis), and diabetes mellitus type 1 and 2. The diagnosis of erythromelalgia relies on classic signs and symptoms: redness, warmth, and burning pain, typically aggravated by heat or exercise and alleviated by cooling. Primary erythromelalgia is diagnosed based on the presence of these classic signs/symptoms and screening for mutations in the SCN9A gene. Secondary erythromelalgia is diagnosed by excluding other diseases associated with these symptoms. Pharmacological treatment and targeted neurological surgery have demonstrated effectiveness primarily in patients with secondary erythromelalgia, where treating the underlying disorder often leads to remission. Aspirin is the preferred drug for erythromelalgia associated with thrombocytopenia or myeloproliferative disorders, with other NSAIDs like anagrelide as alternatives. Managing most patients with primary and secondary erythromelalgia is challenging, and they often resist treatment. Notably, secondary disease due to polycythemia vera and essential thrombocythemia tends to respond favorably to aspirin therapy. Over time, complications such as ulceration, necrosis, and gangrene can develop due to repeated immersion in ice water or chronic cooling of the extremities. The most frequently reported complication is infection, secondary to blistering, ulceration, cyanosis, and gangrene, which can lead to amputation in chronic untreated cases. Malnutrition and hypothermia have been observed in a few instances.

• In a population-based study in the US, the overall age- and sex-adjusted incidence rate per 100,000 people per year was 1.3.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: